Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Chromosomal Abnormalities in Offspring of Young Cancer Survivors: A Population-Based Cohort Study in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Germline mutations in shelterin complex genes are associated with familial glioma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Matteo Lambertini
  • Niels Kroman
  • Lieveke Ameye
  • Octavi Cordoba
  • Alvaro Pinto
  • Giovanni Benedetti
  • Maj-Britt Jensen
  • Shari Gelber
  • Maria Del Grande
  • Michail Ignatiadis
  • Evandro de Azambuja
  • Marianne Paesmans
  • Fedro A Peccatori
  • Hatem A Azim
Vis graf over relationer

Safety of pregnancy in women with history of estrogen receptor (ER)-positive breast cancer remains controversial. In this multicenter case-control study, 333 patients with pregnancy after breast cancer were matched (1:3) to 874 nonpregnant patients of similar characteristics, adjusting for guaranteed time bias. Survival estimates were calculated using the Kaplan-Meier analysis; groups were compared with the log-rank test. All reported P values were two-sided. At a median follow-up of 7.2 years after pregnancy, no difference in disease-free survival was observed between pregnant and nonpregnant patients with ER-positive (hazard ratio [HR] = 0.94, 95% confidence interval [CI] = 0.70 to 1.26, P = .68) or ER-negative (HR = 0.75, 95% CI = 0.53 to 1.06, P = .10) disease. No overall survival (OS) difference was observed in ER-positive patients (HR = 0.84, 95% CI = 0.60 to 1.18, P = .32); ER-negative patients in the pregnant cohort had better OS (HR = 0.57, 95% CI = 0.36 to 0.90, P = .01). Abortion, time to pregnancy, breastfeeding, and type of adjuvant therapy had no impact on patients' outcomes. This study provides reassuring evidence on the long-term safety of pregnancy in breast cancer survivors, including those with ER-positive disease.

OriginalsprogEngelsk
TidsskriftNational Cancer Institute. Journal (Online)
Vol/bind110
Udgave nummer4
Sider (fra-til)426-429
ISSN1460-2105
DOI
StatusUdgivet - 2018

ID: 52341549